All Stories

  1. A novel model to study the impact of gender-affirming therapy on bone in young male mice
  2. Testosterone Therapy in Adult Males with Hypogonadism
  3. Age-Stratified Reference Ranges for Directly Measured Serum Free Testosterone in Community-Dwelling and Healthy Men
  4. OC54 - Role of steroid hormone-binding proteins on the bioactivity of 11-oxygenated androgens
  5. Letter to Editor from Yeap et al: “Endogenous sex steroid hormones, sex hormone-binding globulin, and risk of all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective cohort studies”
  6. The 36th ENTIS (European Network of Teratology Information Services) conference abstracts, September 11th–14th, 2025, Thessaloniki, Greece
  7. The hormonal regulation of men’s sexual desire, arousal, and penile erection: recommendations from the fifth international consultation on sexual medicine (ICSM 2024)
  8. Variability in SHBG assays and the effect thereof on calculated estimates of free testosterone
  9. Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research
  10. LOW 25-HYDROXY-VITAMIN D3 CONCENTRATIONS ARE ASSOCIATED WITH SEXUAL SYMPTOMS IN MIDDLE-AGED AND OLDER MEN
  11. ASSESSMENT OF MALE ANDROGEN EXPOSURE: A SURVEY ON MEASUREMENT AND REPORTING OF TOTAL TESTOSTERONE, SEX HORMONE-BINDING GLOBULIN, AND FREE TESTOSTERONE IN CLINICAL LABORATORIES ACROSS EUROPE
  12. Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses
  13. Determination of Androgen Bioactivity by an In Vitro Assay During Pubertal Transition in Healthy Boys
  14. Association between pubertal timing and bone and body composition in young adult men
  15. A survey on measurement and reporting of total testosterone, sex hormone-binding globulin and free testosterone in clinical laboratories in Europe
  16. No longer to be ignored: Hypophosphatemia following intravenous iron administration
  17. Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses
  18. Hypogonadotropic Hypogonadism as First Presentation of the Severe Neuroendocrine Disorder Caused by RNF216
  19. Use of calculated free testosterone in men: advantages and limitations
  20. Male hypogonadism: pathogenesis, diagnosis, and management
  21. Vitamin D status in children
  22. The Effect of Endurance Exercise on Semen Quality in Male Athletes: A Systematic Review
  23. Evidence-based definition of hypoprolactinemia in European men aged 40–86 years: the European male ageing study
  24. Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men
  25. Comprehensive vitamin d analysis: LC-MS/MS profiling of eight vitamin D metabolites for enhanced biochemical evaluation of vitamin D (PATHO)physiology in the clinical laboratory
  26. (234) TEMPORAL EVOLUTION IN TESTOSTERONE MEASUREMENTS AND DOSES OF TESTOSTERONE REPLACEMENT THERAPY REIMBURSED BY THE BELGIAN HEALTHCARE SYSTEM BETWEEN 2013 AND 2019
  27. Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold
  28. SHBG Gene Polymorphisms and Their Influence on Serum SHBG, Total and Free Testosterone Concentrations in Men
  29. APHRODITE criteria: addressing male patients with hypogonadism and/or infertility owing to altered idiopathic testicular function
  30. Impact of hyperprolactinemia on sexual function
  31. Does testosterone influence the association between sleep and frailty in men: results from the European Male Aging Study
  32. Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor – substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial
  33. Hyponatremia, hypernatremia and impairment of functional, psychological and sexual domains
  34. Testosterone Restores Body Composition, Bone Mass, and Bone Strength Following Early Puberty Suppression in a Mouse Model Mimicking the Clinical Strategy in Trans Boys
  35. Number of CAG repeats and mortality in middle aged and older men
  36. Factors Associated With Circulating Sex Hormones in Men
  37. Sarcopenia‐defining parameters, but not sarcopenia, are associated with cognitive domains in middle‐aged and older European men
  38. The effect of testosterone treatment on bone mineral density in Klinefelter syndrome: A retrospective cohort study
  39. Implementation of a care pathway based computerized order entry system streamlines test ordering and offers tools for benchmarking clinical practice
  40. Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review
  41. The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
  42. Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology
  43. Reproductive hormone levels, androgen receptor CAG repeat length and their longitudinal relationships with decline in cognitive subdomains in men: The European Male Ageing Study.
  44. Bone health in ageing men
  45. Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort
  46. The number of androgen receptor CAG repeats and mortality in men
  47. Inactivation of AR or ERα in Extrahypothalamic Neurons Does not Affect Osteogenic Response to Loading in Male Mice
  48. Binding affinity affecting SHBG SNPs do not majorly affect calculated estimates of free testosterone
  49. Erectile dysfunction predicts mortality in middle-aged and older men independent of their sex steroid status
  50. Calcifediol (25OH Vitamin D3) Deficiency: A Risk Factor from Early to Old Age
  51. Sex Steroid Actions in the Male
  52. Associations of Serum Testosterone and Sex Hormone–Binding Globulin With Incident Cardiovascular Events in Middle-Aged to Older Men
  53. Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: The UK Biobank prospective cohort study
  54. The impact of androgen deprivation therapy on bone mineral density in men treated for paraphilic disorder: A retrospective cohort study
  55. Aging Men With Insufficient Vitamin D Have a Higher Mortality Risk: No Added Value of its Free Fractions or Active Form
  56. Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years)
  57. Self-Reported Shorter Than Desired Ejaculation Latency and Related Distress—Prevalence and Clinical Correlates: Results From the European Male Ageing Study
  58. Novel model to study the physiological effects of temporary or prolonged sex steroid deficiency in male mice
  59. Testosterone Reduces Body Fat in Male Mice by Stimulation of Physical Activity Via Extrahypothalamic ERα Signaling
  60. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
  61. Serum Testosterone is Inversely and Sex Hormone-binding Globulin is Directly Associated with All-cause Mortality in Men
  62. Sociodemographic, lifestyle and medical influences on serum testosterone and sex hormone–binding globulin in men from UK Biobank
  63. High serum FSH is not a risk factor for low bone mineral density in infertile men
  64. Free 25-hydroxyvitamin D, but not free 1.25-dihydroxyvitamin D, predicts all-cause mortality in ageing men
  65. Neoplasia in Turner syndrome: a retrospective cohort study in a tertiary referral centre in Belgium
  66. Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study
  67. High serum FSH is not a risk factor for low bone mineral density in infertile men
  68. Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men
  69. Estrogen receptor alpha signaling in extrahypothalamic neurons during late puberty decreases bone size and strength in female but not in male mice
  70. Nutritional rickets: Historic overview and plan for worldwide eradication
  71. Vitamin D Binding Protein: A Historic Overview
  72. Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism?
  73. Bone mineral density is preserved in men with idiopathic infertility
  74. Testicular vein sampling can reveal gonadotropin-independent unilateral steroidogenesis supporting spermatogenesis
  75. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects
  76. Endogenous testosterone supports spermatogenesis even in the absence of gonadotrophins: evidence from a case report
  77. Free Testosterone Reflects Metabolic as well as Ovarian Disturbances in Subfertile Oligomenorrheic Women
  78. Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: Prospective results from the EMAS
  79. Endogenous testosterone supports spermatogenesis even in the absence of gonadotrophins: evidence from a case report
  80. EAA clinical guideline on management of bone health in the andrological outpatient clinic
  81. Glycemia but not the Metabolic Syndrome is Associated with Cognitive Decline: Findings from the European Male Ageing Study
  82. Effects of sex hormone-binding globulin (SHBG) on androgen bioactivity in vitro
  83. Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis
  84. Natural history, risk factors and clinical features of primary hypogonadism in ageing men: Longitudinal Data from the European Male Ageing Study
  85. Testosterone Treatment in Older Men
  86. Low Free Testosterone Is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone
  87. Evaluation of cognitive subdomains, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D in the European Male Ageing Study
  88. Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study
  89. Androgen Deficiency Exacerbates High-Fat Diet-Induced Metabolic Alterations in Male Mice
  90. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone levels: results from the European Male Ageing Study
  91. Development of and Recovery from Secondary Hypogonadism in Aging Men: Prospective Results from the EMAS
  92. Low free testosterone is associated with hypogonadal symptoms in men with normal total testosterone levels: results from the European Male Ageing Study
  93. Workshop Abstracts (ECTS/IBMS 2015)
  94. Associations Between Sex Steroids and the Development of Metabolic Syndrome: A Longitudinal Study in European Men
  95. What Determines the Difference in DNA Binding Between the Androgen and the Glucocorticoid Receptors?
  96. Androgens and estrogens in skeletal sexual dimorphism
  97. Sensitive routine liquid chromatography–tandem mass spectrometry method for serum estradiol and estrone without derivatization
  98. Late-Onset Hypogonadism